Charles Pastor
Family Medicine · Long Beach, CANPI 1871617316
Payments from drug & device makers
Across 464 payments — averaging $33.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AstraZeneca$718
- Gilead$644
- Sanofi-aventis U.S. LLC$594
- Merck$329
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$7,50048%
- Travel & lodging$2652%
- Food & beverage$7,93251%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $9,259 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 150 | $2,097 |
| AstraZeneca | 44 | $718 |
| Gilead | 37 | $644 |
| Sanofi-aventis U.S. LLC | 30 | $594 |
| Merck | 18 | $329 |
| Pfizer | 18 | $324 |
| Viiv Healthcare Company | 19 | $304 |
| Johnson & Johnson(2 entities) | 10 | $244 |
| GSK | 13 | $242 |
| Amgen(2 entities) | 10 | $174 |
| Smith+Nephew | 8 | $165 |
| Daiichi Sankyo Inc. | 8 | $156 |
| Stryker | 1 | $109 |
| Mannkind Corporation | 4 | $90 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| Boehringer Ingelheim | 2 | $45 |
| Redhill Biopharma Inc. | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $30 |
| Novo Nordisk | 1 | $19 |
| Shionogi Inc | 1 | $13 |
| Alkermes, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$6,152
- SURPASS EVOLVE$109
How this compares
$15,702 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $163,516 |
| JanumetSitagliptin Phos/Metformin Hcl | 90 | $93,699 |
| JanuviaSitagliptin Phosphate | 106 | $87,768 |
| TrulicityDulaglutide | 51 | $85,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $74,582 |
| LinzessLinaclotide | 106 | $65,820 |
| JardianceEmpagliflozin | 67 | $65,364 |
| EliquisApixaban | 71 | $59,731 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $48,022 |
| MyrbetriqMirabegron | 79 | $36,811 |
| FarxigaDapagliflozin Propanediol | 42 | $36,061 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $33,510 |
| TradjentaLinagliptin | 32 | $31,088 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $29,149 |
| MounjaroTirzepatide | 17 | $26,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Dulera | $329 | $193,460227 claims |
| Novo NordiskOzempic | $19 | $163,516144 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $45 | $117,221128 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $242 | $82,54388 claims |
| GileadGenvoya, Descovy | $644 | $81,53227 claims |
| AbbVieLinzess | $9,259 | $65,820106 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $718 | $60,731102 claims |
| PfizerEliquis | $324 | $59,73171 claims |
| Smith+NephewSantyl | $165 | $5,23616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Long Beach
- Steven ReynoldsLong Beach$53M
- Jack VuLong Beach$10.1M
- Amina HaggagNorthridge$112.8M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.